

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bloomage BioTechnology Corporation Limited

華熙生物科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963)

VOLUNTARY ANNOUNCEMENT

DEBUT OF DERMALLURE

The board (“**Board**”) of directors (the “**Directors**”) of Bloomage BioTechnology Corporation Limited (the “**Company**” together with its subsidiaries, the “**Group**”) is pleased to announce that Hyaluronan Soft Tissue Filling Gel (trade name: “**Dermallure**”), a product developed by the Group which contains lidocaine hydrochloride, was approved by the China Food and Drug Administration of the People’s Republic of China on 6 May 2016 and will be on sales since its debut on 3 September 2016. Dermallure belongs to the second aesthetics injection product series of the Group. It applies both sustained-release technology for lidocaine hydrochloride and isotonic efficient cross-linking technique, enabling prolonged pain-killing, delicate figure shaping, enhancement of comfort during injection and reduction of swelling after surgeries. The Board expects that Dermallure will be a powerful boost to product lines of the Group.

By order of the Board

Bloomage BioTechnology Corporation Limited

Zhao Yan

Chairman

Hong Kong, 2 September 2016

As at the date of this announcement, the executive directors are Ms. Zhao Yan, Mr. Jin Xuekun, Mr. Gong Anmin and Ms. Wang Aihua; the non-executive director is Mr. Yau Wai Yan; the independent non-executive directors are Ms. Zhan Lili, Mr. Li Junhong and Mr. Xue Zhaofeng.